Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials

doi:10.5306/wjco.v13.i5.388

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6371)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

462

WORD

120

HTML

3900

Figures (1-1)

197

Tables (1-2)

231

Sum=4910

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

230

Download

597

Sum=827

Publishing Process of This Article

Item

Count

Browse

263

Download

371

Sum=634

May 24, 2022 (publication date) through May 12, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Clin Oncol. May 24, 2022; 13(5): 388-411
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.388

Open in New Tab Full Size Figure Download Figure

Figure 1 Article selection flow diagram. RCTs: Randomized controlled trials.

Citation: Poulose JV, Kainickal CT. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World J Clin Oncol 2022; 13(5): 388-411
URL: https://www.wjgnet.com/2218-4333/full/v13/i5/388.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i5.388